Longitudinal Data Stand Out at AD/PD Imaging Satellite
The 11th AD/PD Conference hosted a day-long exchange of new imaging data and discussion of current challenges for the research community in these two disorders...
589 RESULTS
Sort By:
The 11th AD/PD Conference hosted a day-long exchange of new imaging data and discussion of current challenges for the research community in these two disorders...
Scientists quipped about Florence as a fitting setting for what they perceive to be a resurgence of the amyloid hypothesis after a beleaguered period of setbacks...
The Alzheimer’s Disease Neuroimaging Initiative steering committee gathered to exchange the latest developments in ADNI 2...
Scientists have turned their attention toward testing therapies in early-stage patients who have underlying brain pathology but little to no functional impairment...
Adding insult to injury, many patients with a movement disorder get dementia, too...
Growing evidence suggests that neurons begin faltering decades before cognitive symptoms in AD, but identifying the molecular culprits at play has proven challenging...
Among global initiatives aimed at understanding how biomarkers elucidate the progression of Alzheimer’s disease, DESCRIPA appears to do much with little...
Scientists worldwide now perform amyloid imaging on scores of research participants to figure out how Aβ buildup relates to other markers of neurodegeneration...
Like a blue moon, could oligomeric amyloid-β in the cerebrospinal fluid (CSF) be too rare to be informative?...
Clifford Jack's hypothetical model showing biomarkers emerging at different stages of AD surged to the top of the Most-Popular-Slide-at-Conferences chart...
In a snowy mountain town in Austria, 75 scientists traded data and discussion of AD treatment approaches...
The quest for health insurance coverage of brain amyloid scanning just took a twist...
Merck’s BACE inhibitor development program began enrolling last month for an 18-month Phase 2/3 trial of its lead compound (MK-8931) in mild to moderate AD...
With growing recognition that AD kicks off years before cognitive symptoms appear, scientists have ramped up efforts to understand early biomarker changes...
Merck announced this week that it has begun enrolling for the largest clinical trial of a β-secretase (BACE1) inhibitor in Alzheimer’s disease patients...